Candel Therapeutics, Inc.

NasdaqGM CADL

Candel Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2024

Candel Therapeutics, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Candel Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 10.33 M.
Candel Therapeutics, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 4.40 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGM: CADL

Candel Therapeutics, Inc.

CEO	Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
IPO Date	July 27, 2021
Location	United States
Headquarters	117 Kendrick Street
Employees	42
Sector	Health Care
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Key trends

Past 5 years